Nxera Pharma Co., Ltd.

4565

JP3431300007

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:30:00 2026-05-08 am EDT			5-day change	1st Jan Change
1,167.00 ^JPY	+5.90%		+22.58%	+41.11%

Apr. 23	Santhera Pharmaceuticals Holding AG Announces Chief Executive Officer Changes	CI
Apr. 20	Ruled by Headlines

Nxera Pharma Co., Ltd. Reaches Third R&D Milestone Under Collaboration with Abbvie

Published on 04/20/2026 at 06:21 am EDT

S&P Capital IQ

NXERA PHARMA CO., LTD.

+5.90%

ABBVIE INC.

-1.13%

Nxera Pharma Co., Ltd. announced that it has reached a third R&D milestone under its multi-target discovery collaboration with AbbVie focused on neurological diseases, resulting in a payment of USD 10 million to Nxera. Nxera and AbbVie entered this multi-target collaboration in 2022 to leverage Nxera?s NxWave? platform to discover novel medicines targeting G protein-coupled receptors (GPCRs) associated with neurological disease.

This current milestone relates to the identification of validated and differentiated ?hit? molecules against a neurology target. Under the terms of the agreement, Nxera is eligible to receive up to USD 40 million in near-term research milestones, as well as further potential option, development and commercial milestones totalling up to USD 1,200 million, plus tiered royalties on global sales.

This is the third milestone received in this collaboration; the first milestone was achieved in June 2024 and the second milestone in September 2025.

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Approximate price	Change	5d. change	Capi.
	NXERA PHARMA CO., LTD.	1,167.00JPY	+5.90%	+22.58%	646M
	ABBVIE INC.	202.71USD	-1.13%	-4.07%	359B

Latest news about Nxera Pharma Co., Ltd.

Apr. 23	Santhera Pharmaceuticals Holding AG Announces Chief Executive Officer Changes	CI
Apr. 20	Ruled by Headlines
Apr. 20	Nxera Pharma Co., Ltd. Reaches Third R&D Milestone Under Collaboration with Abbvie	CI
Apr. 20	Nxera Pharma to Receive $10 Million Milestone from AbbVie for Neurology Collaboration	MT
Apr. 20	AbbVie Makes $10 Million Milestone Payment to Nxera Pharma Under Collaboration	MT
Apr. 20	Nxera Pharma Co Ltd - to receive US$10 million milestone payment from AbbVie under collaboration targeting neurological diseases	RE
Apr. 13	Nxera Pharma Co., Ltd. Initiates and Doses First Patient in Phase 2 Trial of Nbi-1117570 for Adults with Schizophrenia	CI
Apr. 13	Nxera Pharma Partner Neurocrine Biosciences Doses First Patient in Phase 2 Schizophrenia Study	MT
Apr. 12	Nxera Pharma Co Ltd - Nxera Pharma's partner Neurocrine Biosciences doses first patient in phase 2 trial of NBI-1117570 for adults with schizophrenia	RE
Apr. 08	Nxera Secures Milestone Payment in Eli Lilly Collaboration	MT
Apr. 08	Nxera Pharma Achieves Second Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases	CI
Apr. 08	Nxera Pharma Co - achieves second development milestone in collaboration with Eli Lilly targeting metabolic diseases	RE
Apr. 06	Nxera Pharma Co., Ltd. - Shareholder/Analyst Call
Apr. 01	Nxera Partner Centessa to Be Acquired by Lilly, Retains Royalty Rights	MT
Mar. 25	Nxera Pharma Co., Ltd. Appoints Takeo Morooka as External Director, Effective March 25, 2026	CI

Chart Nxera Pharma Co., Ltd.

Duration

Period

4565: Dynamic Chart

Company Profile

Nxera Pharma Co Ltd, formerly known as Sosei Group Corp, is a Japan-based company engaged in the biopharmaceutical business that handles from drug research (drug discovery) to development and sale. The Company is mainly engaged in the pharmaceutical business. The Company is engaged in drug discovery, translational medicine, preclinical and early clinical development, as well as the research and development, import/export, packaging, and sale of pharmaceuticals. The Company also conducts structural analysis of G protein-coupled receptors (GPCRs), creates initial lead compounds, and searches for candidate products using StaR technology.

Employees

382

Sector

Pharmaceuticals

More about the company